Immune Network Starts Canadian Clinical Trial.

Business Editors

VANCOUVER, B.C.--(BUSINESS WIRE)--Feb. 27, 2001

Immune Network Ltd. (OTCBB:IMMKF) (CDNX:IMM.) reports that it has commenced a Canadian clinical trial to provide additional safety and pharmacokinetic evidence in support of the development of its anti-inflammatory drug for treating Alzheimer disease.

Under the management of CroMedica Prime, the trial will involve 24 healthy volunteers between the ages of 50 and 80. The objective of this clinical trial is to determine further clinical characteristics of dapsone alone and in combination with donepezil (a current drug for Alzheimer disease). Data from this drug interaction trial will enable further development of IQ201, Immune Network's new Alzheimer disease drug candidate based on dapsone. This trial will be completed in about three months.

CroMedica Prime, a Phase I clinical trials unit of CroMedica, is a novel research partnership that pairs industry and academic expertise with state-of-the-art facilities. Located in the Vancouver General Hospital, CroMedica Prime represents a unique partnership among CroMedica, the Vancouver Hospital and Health Sciences Centre, the University of British Columbia and the BIRC Corporation. The facility is particularly suited for specialized, technologically intensive research endeavours from Phase I through proof-of-concept investigations.

Immune Network is also continuing with its DAD2000 trial, a multi-center prospective Phase 2 clinical trial, now active in over 15 centers in four countries. The DAD2000 trial is designed to provide definitive data further supporting the clinical development of IQ201.

Alzheimer disease (AD) is one of the leading causes of death in the elderly population. One in 10 people over 65 and nearly half of those over 85 have Alzheimer disease. Immune Network's therapeutic approach is not aimed at the original causes of the disease, but rather the final step that leads to brain cell death. For diseases that have many contributing factors, such as Alzheimer disease, aiming a drug at a final step of the disease process can often be more fruitful than aiming a drug at one of many upstream factors. Immune Network's drug candidate appears to "soothe the inflamed brain," blocking brain inflammation through a broad spectrum of action.

Immune Network also reports the appointment of Ms. Rupinder Bagri as Director of Investor Relations. Ms. Bagri has been with the company since June of 1999.

About Immune Network

As a biotech merchant developer, Immune Network's principal strategy is to identify outstanding commercial opportunities for new drug treatments and to take them closer to market through rapid completion of critical milestones. Completion of these milestones may be followed by licensing, alliances or spin-offs with the goal of realizing a much faster return on investment than would typically be realized by traditional biotech companies. Immune Network's drug development portfolio currently includes therapeutics for Alzheimer Disease, AIDS, Herpes, Asthma, Cancer, Hepatitis, and Dermatitis.

Immune Network also maintains a holdings portfolio in a number of technology companies through its majority owned subsidiary, BC Research Inc.

To learn more about Immune Network Ltd., please visit our website: www.immunenetwork.com

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward looking statements that are not historical facts and are subject to risks and uncertainties which could cause actual results to differ materially from those set forth in or implied herein. These risks are described in detail in the company's Securities and Exchange Commission filings.

The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.